1. Home
  2. MGN vs CTSO Comparison

MGN vs CTSO Comparison

Compare MGN & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MGN

Megan Holdings Limited Ordinary Shares

N/A

Current Price

$1.80

Market Cap

43.0M

Sector

N/A

ML Signal

N/A

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.67

Market Cap

45.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGN
CTSO
Founded
2020
1997
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.0M
45.9M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
MGN
CTSO
Price
$1.80
$0.67
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
33.0K
124.7K
Earning Date
01-29-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
$13,484,571.00
$36,979,520.00
Revenue This Year
N/A
$7.26
Revenue Next Year
N/A
$9.78
P/E Ratio
$23.41
N/A
Revenue Growth
N/A
23.89
52 Week Low
$1.30
$0.60
52 Week High
$8.63
$1.61

Technical Indicators

Market Signals
Indicator
MGN
CTSO
Relative Strength Index (RSI) N/A 46.78
Support Level N/A $0.61
Resistance Level N/A $0.77
Average True Range (ATR) 0.00 0.06
MACD 0.00 0.00
Stochastic Oscillator 0.00 48.19

Price Performance

Historical Comparison
MGN
CTSO

About MGN Megan Holdings Limited Ordinary Shares

Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: